NCT04343261View on ClinicalTrials.gov

Convalescent Plasma in the Treatment of COVID 19

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

July 23, 2020

Study Completion Date

August 13, 2020

Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)COVIDCoronavirus
Interventions
BIOLOGICAL

Convalescent Plasma

treatment with 2 Units of convalescent plasma

Trial Locations (1)

06105

Trinity Health Of New England, Hartford

All Listed Sponsors
lead

Trinity Health Of New England

OTHER

NCT04343261 - Convalescent Plasma in the Treatment of COVID 19 | Biotech Hunter | Biotech Hunter